Drug Trial Radar · NCT03887455
A Study to Confirm Safety and Efficacy of Lecanemab in Participants With Early Alzheimer's Disease
Last checked: Nov 20, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
1,906
Actual
Start
Mar 27, 2019
Primary completion
Dec 31, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Eisai Inc.Eisai
- Sponsor type
- Industry
- Collaborators
- Biogen
- First posted
- Mar 25, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years, up to 90 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will be conducted to evaluate the efficacy of lecanemab in participants with early Alzheimer's disease (EAD) by determining the superiority of lecanemab compared with placebo on the change from baseline in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) at 18 months of treatment in the Core Study. This study will also evaluate the long-term safety and tolerability of lecanemab in participants with EAD in the Extension Phase and whether the long-term effects of lecanemab as measured by the CDR-SB at the end of the Core Study is maintained over time in the Extension Phase. Extension Phase Part B will continue dosing with lecanemab in countries where lecanemab may not be commercially available.
Conditions
- Early Alzheimer's Disease
Interventions
Lecanemab IVDrug
Administered as IV infusion.
PlaceboDrug
Biweekly (once every 2 weeks) administered as IVinfusion.
Lecanemab SCDrug
Administered weekly as a SC injection.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Core Study: Change from Baseline in the CDR-SB at 18 MonthsTime frame: Baseline, 18 months
- Extension Phase: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs)Time frame: From first dose of study drug up to approximately 51 months (including 3 months follow up) for the extension phase
- Extension Phase: Change from Core Study Baseline in CDR-SBTime frame: Baseline up to Month 66
- Extension Phase Part B: Number of Participants Exposed to LecanemabTime frame: From 48th month in extension phase part A to the end of extension phase part B (up to 24 months)
Locations
247 sites in 14 countries. Site status is shown where the registry gives one.
Banner Alzheimer's Institute- Clinical Trials Department
Phoenix, Arizona
Banner Sun Health Research
Sun City, Arizona
Neurological Associates of Tucson dba Center for Neurosciences
Tucson, Arizona
Neurology Center of North Orange County
Fullerton, California
Irvine Clinical Research
Irvine, California
University of California - Los Angeles
Los Angeles, California
Pacific Neuroscience Medical Group
Oxnard, California
Stanford University Medical Center
Palo Alto, California
Pacific Research Network, Inc
San Diego, California
Sharp Neurocognitive Research Center
San Diego, California
UCSF Memory and Aging Center
San Francisco, California
Apex Research Institute
Santa Ana, California
St Joseph Heritage Healthcare
Santa Rosa, California
ImmunoE Research Center
Centennial, Colorado
Mile High Research Center
Denver, Colorado
Associated Neurologists of Southern Connecticut
Fairfield, Connecticut
Institute for Neurodegenerative Disorders
New Haven, Connecticut
Yale University School Of Medicine
New Haven, Connecticut
Research Center for Clinical Studies, Inc.
Norwalk, Connecticut
Georgetown University Hospital
Washington D.C., District of Columbia
JEM Research Institute
Atlantis, Florida
Bradenton Research Center, Inc.
Bradenton, Florida
Linfritz Research Institute, Inc.
Coral Gables, Florida
Brain Matters Research
Delray Beach, Florida
Neuropsychiatric Research Center of Southwest FL
Fort Myers, Florida
Infinity Clinical Research
Hollywood, Florida
Clincloud, LLC
Maitland, Florida
BioMed Research Institute
Miami, Florida
Finlay Medical Research
Miami, Florida
CCM Clinical Research Group
Miami, Florida
Advance Medical Research Center
Miami, Florida
Advanced Clinical Research Network
Miami, Florida
Gonzalez MD & Aswad MD Health Services
Miami, Florida
Vitae Research Center
Miami, Florida
Miami Jewish Health Systems
Miami, Florida
Allied Biomedical Research (Clinical Trial)
Miami, Florida
Pharmax Research of South Florida, Inc
Miami, Florida
IMIC, Inc.
Miami, Florida
Visionary Investigators Network
Miami, Florida
Visionary Investigators Network
Miami, Florida
Showing 40 of 247 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.